EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
The deadline for Jinjing has been extended to 5pm on 23rd October 2015.
EKF announces that results from a study involving EKF Molecular’s PointMan™ DNA enrichment technology have been published in Clinical Cancer Research.
Study using PointMan DNA enrichment technology have been accepted for publication in Clinical Cancer Research.
EKF announces that it is exhibiting its range of Maternal and Women's Health products at the XXI FIGO World Congress - the International Federation of Gynecology and Obstetrics - in Vancouver, Canada, 4-9th October.
EKF Diagnostics announces its unaudited interim results for the six months ended 30 June 2015.
Studies confirm utility of PointMan for molecular analysis of CTCs and circulating DNA in liquid biopsies